PRESS RELEASE
Apmonia Therapeutics announces the launch of the THROMBOTAX program with the support of the ANR
(French National Research Agency)
Apmonia Therapeutics’ technology platform, specialized in the therapeutic targeting of the extracellular matrix, shows strong potential in the field of cardiovascular pathologies and thrombosis Reims,